Protagonist Therapeutics, Inc.

Protagonist Therapeutics Misses on EPS, Stock Down 0.57%

Protagonist Therapeutics reported a larger-than-expected loss per share, which contributed to a slight decline in stock price. The lack of revenue figures and forward guidance may raise concerns among investors about the company's near-term performance. The stock's reaction reflects cautious sentiment as the company continues to navigate its clinical development efforts.